agataki S. Treatment of methimazole-induced agranulocytosis using recombinant human granulocyte colony-stimulating factor (rhG-CSF). J Clin Endocrinol Metab 77:1356-1360, 1993.
155. Godley AF, Stanbury JB: Preliminary experience in the treatment of hyperthyroidism with potassium perchlorate. J Clin Endocrinol Metab 14:70, 1954.
156. Krevans JR, Asper SP Jr, Rienhoff WF Jr: Fatal aplastic anemia following use of potassium perchlorate in thyrotoxicosis. J Amer Med Assn 181:162, 1962.
157. Georges JL, Normand JP, Lenormand ME, Schwob J. Life-threatening thyrotoxicosis induced by amiodarone in patients with benign heart disease. European Heart Journal 13:129-132, 1992.
158. Lazarus JH, Addison GM, Richards AR, Owen GM: Treatment of thyrotoxicosis with lithium carbonate. Lancet 2:1160, 1974.
159. Turner JG, Brownlie BEW, Rogers TGH: Lithium as an adjunct to radioiodine therapy for thyrotoxicosis. Lancet 1:614, 1976.
159.1. Mercado M, Mendoza-Zubieta V, Bautista-Osorio R, Espinoza-De Los Monteros AL. Treatment of hyperthyroidism with a combination of methimazole and cholestyramine. J Clin Endocrinol Metab 81:3191-3193, 1996.
160. Reinwein D, Klein E: Der Einfluss des anorganischen Blutjodes auf den Jodumstaz der menschlichen Schilddruse. Acta Endocrinol 35:485, 1960.
161. Thompson WO, Thorp EG, Thompson PK, Cohen AC: The range of effective iodine dosage in exophthalmic goiter. II. The effect on basal metabolism of the daily administration of one-half drop of compound solution of iodine. Arch Intern Med 45:420, 1930.
162. Friend DG: Iodide therapy and the importance of quantitating the dose. N Engl J Med 263:1358, 1960.
165. Emerson CH, Anderson AJ, Howard WJ, Utiger RD: Serum thyroxine and triiodothyronine concentrations during iodide treatment of hyperthyroidism. J Clin Endocrinol Metab 40:33, 1975.
166. Shanks RG, Hadden DR, LoweDC, McDevitt DB, Montgomery DAD: Controlled trial of propranolol in thyrotoxicosis. Lancet 2:1969.
167. Mazzaferri EL, Reynolds JC, Young RL, Thomas CN, Parasi AF: Propranolol as primary therapy for thyrotoxicosis. Arch Intern Med 136:50, 1976.
168. Wiener L, Stout BD, Cox JW: Influence of beta sympathetic blockade with propranolol on the hemodynamics of hyperthyroidism. Am J Med 46:227, 1969.
169. Saunders J, Hall SEH, Crowther A, Sonksen PH: The effect of propranolol on thyroid hormones and oxygen consumption in thyrotoxicosis. Clin Endocrinol 9:67, 1978.
170. Georges LP, Santangelo RP, Mackin JF, Canary JJ: Metabolic effects of propranolol in thyrotoxicosis. I. Nitrogen, calcium, and hydroxyproline. Metabolism 24:11, 1975.
171. Hadden DR, Montgomery DAD, Shanks RG, Weaver JA: Propranolol and iodine-131 in the management of thyrotoxicosis. Lancet 2:852, 1968.
172. Pimstone N, Marine N, Pimstone B: Beta-adrenergic blockade in thyrotoxic myopathy. Lancet 2:1219, 1968.
173. Smith CS, Howard NJ: Propranolol in treatment of neonatal thyrotoxicosis. J Pediatr 83:1046, 1973.
174. Rosenberg I: Thyroid storm. N Engl J Med 283:1052, 1970.
174a. Fraser T, Green D. Weathering the storm: beta-blockade and the potential for disaster in severe hyperthyroidism. Emergency Med 13:376-380, 2001
174b. Ikram H. Haemodynamic effects of beta-adrenergic blockade in hyperthyroid patients with and without heart failure. Br Med J 1:1505-1507, 1977.
175. Bewsher PD, Pegg CAS, Steward DJ, Lister DA, Michie W: Propranolol in the surgical management of thyrotoxicosis. Ann Surg 180:787, 1974.
175.1 El Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedüs L, Nielsen CH. Clin Immunol. 2009 Mar;130(3):252-8 Treatment of Graves’ disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies.
175.2 Heemstra KA, Toes RE, Sepers J, Pereira AM, Corssmit EP, Huizinga TW, Romijn JA, Smit JW.Eur J Endocrinol. 2008 Nov;159(5):609-15 Rituximab in relapsing Graves’ disease, a phase II study.
175.21 El Fassi D, Nielsen CH, Junker P, Hasselbalch HC, Hegedüs L. Systemic adverse events following rituximab therapy in patients with Graves’ disease.J Endocrinol Invest. 2011 Jul-Aug;34(7):e163-7.
175.3 Neumann S, Eliseeva E